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Philippe Mayaud, MD,*§ Matthew F. Chersich, PhD,* and Sinead Delany-Moretlwe, PhD*Objective: To estimate the incidence; persistence and correlates of human
papillomavirus (HPV) infection and anogenital warts (AGW) among men
living with human immunodeficiency virus (MLHIV).
Methods: Overall, 304 MLHIV 18 years or older were enrolled and
attended follow-up visits at 6, 12, and 18 months. Clinicians examined
for AGW, collected blood, and penile swabs for HPV testing (Roche Linear
Array) at each visit. Time to AGW incidence or clearancewas estimated by
Kaplan-Meier method. Factors associated with persistent HPV infection
and AGW clearance were evaluated with generalized estimating equations
and Cox regression, respectively.
Results: Mean age of participants was 38 years (standard deviation,
8 years); 25% reported more than 1 sexual partner in the past 3 months.
Most (65%) participants were on antiretroviral treatment (ART) with a me-
dian CD4+ count of 445 cells/μL (interquartile range, 328–567). Prevalence
of HPV infection and AGW at enrolment were 79% (224 of 283) and 12%
(36 of 304), respectively. Two hundred fifty-nine men were followed up for
a median (interquartile range) 1.4 years (0.5–1.7 years). Incidence of any-
genital HPV infection was 2.9 (95% confidence interval, 1.5–5.5) per 100
person-years. Persistence of any-genital HPV infection was 35% (68 of
192) andwas higher amongMLHIVwith lowCD4+ count (adjusted odds ra-
tio, 3.54; 95% confidence interval, 2.07–6.05). Incidence of AGW was 1.4
per 100 person-years. Men living with human immunodeficiency virus with
high CD4+ count were more likely to clear AGW than those with low CD4
count (adjusted hazard ratio, 3.69; 95% confidence interval, 1.44–9.47). No
associations were observed between persistent genital HPV infection, AGW
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Sexually Transmitted Diseases • Volume 46, Number 5, May 2019Conclusions: Human immunodeficiency virus–positive men have a high
burden of genital HPV infection and AGW. The ART and HPV vaccine
could reduce this burden.
Human papillomavirus (HPV) is the most common sexuallytransmitted infection worldwide.1 Genital HPV causes a sub-
stantial burden of disease burden in men. High-risk (HR) HPV
types cause about 50% of the estimated 26,000 annual incident pe-
nile cancer cases that occur worldwide.2 Low-risk (LR) HPV types
6 and 11 are responsible for 90% of anogenital warts (AGW).3
Persistence of genital HPV infection is important for pro-
gression to disease.4 Human immunodeficiency virus (HIV) infec-
tion is associated with an increased risk of persistence and
progression to disease.5,6 People living with HIV have a higher
prevalence of genital HPV infection and aremore likely to be infected
with multiple HPV types compared with HIV-negative individuals.7
In people living with HIV, AGW tend to be florid and are often dif-
ficult to treat, particularly in resource-constrained settings.8 These
poor clinical outcomes are due to immunosuppression which
impairs the clearance of HPV infections.9 Although the natural
history of cervical cancer and progression from HPV infection to
development of invasive cervical disease has been well
documented,10–12 relatively little is known about the natural his-
tory of genital HPV infection and related diseases in men,13,14 es-
pecially among predominantly heterosexual men living with HIV
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Chikandiwa et al.shown to be a strong predictor of persistent cervical HPV infec-
tion, its role in predicting persistent genital HPV infection in
men is not clear.15
The development and roll out of highly efficacious HPV
vaccines is arguably one of the biggest public health innovations
of the 21st century. In 2014, the South African government intro-
duced HPV vaccination into the national immunization schedule,
and the vaccine is currently only being delivered to girls with a goal
to prevent cervical cancerwhich is a leading cause of death inwomen.
Results from high-income countries, such as Australia, show signifi-
cant declines in the cases of AGW among vaccinated women and a
herd-immunity effect in unvaccinated heterosexual men.16 In settings
with a high HIV prevalence, the impact of a girls-only program on
herd immunity in men may be reduced.17 Data from Australia have
also shown that men who have sex with men will not be protected
by herd immunity from a girls-only program.16
We established a cohort study of predominately heterosexual
MLHIV to learn about the epidemiology of HPV in this population
and help inform future HPV prevention policies among men in
South Africa. In this analysis, we estimated the prevalence, incidence,
persistence and clearance of genital HPV infections and AGW,
and the correlates of these outcomes. Based on this evidence, we
postulatewhat benefits might accrue fromHPV vaccination in males.METHODS
Study Design, Population, and Data Collection
The design of the cohort study has been published previ-
ously.18 In brief, 304 HIV seropositive men 18 years or older
who reported sexual activity in the 3 months before enrolment
were recruited from antiretroviral treatment (ART) clinics in
inner-city Johannesburg. Participants were enrolled irrespective
of sexual orientation and followed up every 6 months for up to
18 months. Data on sociodemographic, behavioral and clinical
characteristics were collected by an interviewer-administered
questionnaire at each visit. In addition, participants completed sen-
sitive questions on sexual behavior using a computer-assisted self-
interview, to improve privacy. The presence of AGWwas assessed
at each visit by a trained clinician during a standardized genital ex-
amination. According to National Sexually Transmitted Infection
Management Guidelines, men with AGWat any visit were treated
with Podophyllin 20% solution at weekly intervals until lesions
disappear.19 Cure of AGWwas established by genital examination
before each study visit.
Sample Collection
Venous blood was taken at each visit to test for CD4+ cell
count (FACScount, BD; BD Biosciences, San Jose, CA) and
HIV-1 plasma VL (PVL) using Roche Taqman (Roche Diagnostics,
Mannheim, Germany). A genital sample for HPVDNA testing was
collected by rubbing a cotton swab around the glans penis, coronal
sulcus, and ventral surface of the penis as previously described.12,18
Swabs were stored at −70°C before HPV DNA testing.
Laboratory Methods
The CD4+ counts and HIV-1 PVL were measured using
FACScount, BD (BDBiosciences) and Roche Taqman (Roche Di-
agnostics), respectively. Participants who had a CD4+ count less
than 350 cells/μL were referred to an HIV clinic for ART initia-
tion, in accordance with the national guidelines at the time.20
The HPV detection and genotyping was performed using
an identical method at enrolment and at last follow-up visit, testing
was done only for these 2 visits due to cost constraints. The348 SexuMagNA Pure LC DNA Isolation Kit I (Roche Diagnostics) was
used to extract HPV DNA from the swabs. The HPV genotype
distributions were then assessed by the Roche Linear Array assay
(RLA; Roche Diagnostics). The HPV 16 and HPV 18VLs (copies
per million human cells) were quantified at enrolment on samples
that were positive for these types using quantitative duplex real-
time polymerase chain reaction method.21 This method allows
the HPV 16, HPV 18, and albumin gene copy number to be quan-
tified in the same assay. The human β-globin gene served as an in-
ternal control for cellular adequacy and extraction efficiency.
Results for samples with an inadequate control were reported as
invalid and excluded from analysis. Of the 272 available for
HPV testing, 13 (5%) had inadequate control.
Definition of Genital HPV Infection and
AGW Outcomes
Groups of HPV genotypes were categorized as follows:
(i) any HPV infection, that is, detection of at least 1 of the 37
HPV genotypes that can be isolated by the RLA; (ii) any
HR-HPV infection, that is, detection of at least 1 of the following
HPV genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or
68; (iii) any LR-HPV infection, that is, detection of at least 1 of
the following HPV genotypes: 6, 11, 26, 40, 42, 53, 54, 55, 61,
62, 66, 69, 70, 71, 72, 73, 81, 83, 84, IS39 or CP6108; (iv) any
alpha-7 infection, that is, detection of at least 1 of the following
HR-HPVgenotypes: 18, 45; 39 or 59; and (v) any alpha-9 infection,
that is, detection of at least 1 of the following HR-HPV genotypes:
16, 31, 33, 35, 52 or 58. The HPV 16 or 18 VL were log trans-
formed to base 10, to normalize distribution, as previously de-
scribed.21 Prevalent genital HPV infection was defined as
detection of HPVDNA at enrolment. The HPVDNA infection out-
comes at final visit were defined as (i) incident infection, that is, de-
tection of any HPV DNA type that was not detected at enrolment;
(ii) persistence, that is, detection of the same HPV DNA type that
was detected at enrolment; and (iii) clearance, that is, absence of de-
tection of an HPV DNA type that was detected at enrolment.
Prevalent AGW was defined as detection of genital warts
during clinical examination at enrolment. AGWoutcomes at each
follow-up visit were defined as (i) incident, that is, detection of
AGW in a participant that had no AGWat enrolment; (ii) persistent,
that is, detection of AGWat all follow-up visits in a participant who
had AGW at enrolment; and (iii) clearance, that is, the absence of
detection of AGW at all follow-up visits in a participant who had
AGWat enrolment.
Eight variables measuring the HIV disease of participants
were generated, including ART status, CD4+ count, and PVL at en-
rolment. Controlled HIV disease at enrolment was defined as being
on ART for at least 6 months, with CD4+ count of 350 cells/μL or
higher and undetectable HIV-1 PVL (ie, <40 copies/mL). High sta-
ble CD4+ count was defined as a CD4+ count greater than 500 cells
at all follow-up visits. Sustained HIV virological control was de-
fined HIV-1 PVL less than 40 copies/mL at all follow-up visits.
Statistical Analysis
Descriptive statistics were used to summarize the preva-
lence of genital HPV infection and AGW. The incidence rate and
95% confidence interval (95% CI) of genital HPV infection were
estimated by Kaplan-Meier method. Person timewas calculated as
the time from the date of sample collection at enrolment to the date
of sample collection at the final follow-up visit. Persistence of
HPV infection was computed by expressing the number of persis-
tent infections as a proportion of prevalent infections at enrolment.
Associations between any persistent genital HPV infection
and exposure variables were evaluated using generalized estimatingally Transmitted Diseases • Volume 46, Number 5, May 2019
Genital HPV Infection and Anogenital Warts in Menequations (GEE) with robust standard errors (vce) to account for
multiple HPV genotypes and multiple infection states (persistence
and clearance) that could occur within each participant.22 The unit
of analysis was infections, not men, as the outcome measured was
persistence of an HPV infection in follow up (men could have more
than 1 infection). The exchangeable correlation option was used to
account for within-participant correlation of the different HPV
genotypes. Separate GEE models were run for each of the 8 HIV-
related variables and for HPV VL at enrolment. These models
identified independent predictors for persistent infection after
adjusting for potential confounders (ie, age, citizenship, employ-
ment status, consistent condom use, circumcision, and AGW) asso-
ciated with the outcome in bivariate analysis at P less than 0.10.23
The median time to AGW incidence or clearance was esti-
mated using the KM method, and differences were assessed for
significance using theMantel-Haenszel log rank test. Associations
between AGW clearance and exposure variables were assessed
using Cox proportional hazards regression. Adjusted Cox regres-
sion models were run to identify independent risk factors using
the same model-building approach as described above. Risk factor
analysis for incident AGWwas not run due to low incidence rates.
All data were analyzed using Stata version 13 (Stata Statistical
Software; Stata Corporation, College Station. TX).Ethics Statement
Ethical approval for the study was obtained from the Wits
Human Research Ethics Committee (reference numbers: M111191
and M160859). All study participants provided written, informed
consent after full explanation of the study objectives and






















Any LR types¶ 166
HPV 6 35
HPV 11 18
* Detection of the same HPV DNA type that was detected at enrolment.
† Alpha-7 types include: HPV 18, 39, 45, and 59.
‡ HR-HPV types include: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 5
§ Alpha-9 types include: HPV 16, 31, 33, 35, 52, and 58.
¶ LR-HPV types include: HPV 6, 11, 40, 42, 54, 55, 61, 62, 66, 67, 69. 70,
Sexually Transmitted Diseases • Volume 46, Number 5, May 2019RESULTS
Study Population
The study population has been described elsewhere.18 A total
of 304 MLHIV were enrolled between March 2011 and October
2012. Participants had mean age of 38 years (standard deviation,
8 years); 25% reported more than 1 sexual partner in the past
3 months; and only 5% (n = 15) reported ever having sex with
other men. At enrolment, the majority were already taking ART
(65%, n = 197), for a median duration of 33 months (interquartile
range [IQR], 15–58), of whom about half (n = 106, 54%) were vi-
rologically suppressed with median CD4+ count of 445 cells/μL
(IQR, 328–567). Almost one fifth (n = 55, 18%) of MLHIV were
classified as having controlled HIV disease at enrolment and (28,
11% had HIV virological control over all study follow-up visits.
The prevalence of any-genital HPV infection at enrolment
was 79% (224 of 283), and the prevalence of AGW was 12%
(36 of 304). The median HPV 16 VL was 6.32 log10/10
6 cells
(IQR, 5.81–7.62) among the 15 men with sufficient sample for
this measure (testing was not possible on 23 HPV 16-positive
men). The median HPV 18 VL was 6.01 log10/10
6 cells (IQR,
5.11–6.33) for 5 of the 21 men positive for this type. Overall,
287 (95%) of the men attended at least 1 follow-up visit.Incidence and Persistence of Genital HPV Infection
A total of 259 men (90% of participants with a follow-up
visit) had genital HPV DNA results at both enrolment and final
visits as some of the HPV results were invalid or missing. The in-
cidence of any-genital HPV infection was 2.9 (95% CI, 1.5–5.5)
per 100 person-years. The proportion of any LR-HPV incident in-
fection (13%) was higher than that for any HR-HPV types (6%,Persistence* Clearance†
n (%) n (%)
68 (35) 124 (65)
28 (12) 98 (88)
10 (17) 49 (83)
18 (21) 68 (79)
10 (35) 19 (65)
0 (0) 20 (100)
0 (0) 6 (100)
1 (9) 10 (91)
1 (3) 31 (97)
2 (17) 10 (83)
2 (10) 18 (90)
1 (4) 23 (96)
3 (18) 14 (82)
2 (18) 9 (82)
0 (0) 20 (100)
5 (23) 17 (87)
2 (10) 18 (90)
55 (33) 111 (67)
7 (20) 28 (80)
3 (17) 15 (83)
9, 68.
71, 72, 73, 81, 83, 84, IS39, and CP6108.
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Chikandiwa et al.P = 0.04, data not shown). The persistence of any HPV infection
was 35% (68 of 192). HPV 16 had comparatively higher persis-
tence compared with HPV 18 (35% vs. 0%), whereas the corre-
sponding figures for HPV 6 and HPV 11 types were 20% and
17%, respectively (Table 1).
Factors Associated With Persistent Genital
HPV Infection
Persistent genital HPV infection was associated with CD4+
count with a stepwise increase in odds with each decrease in CD4
count category (Table 2). Persistence was higher among MLHIV
with low CD4+ count (<200 vs. >500 cells/μL; adjusted odds ratio
[aOR], 3.54; 95% CI, 2.07–6.05; P < 0.001). Men with detectable
HIV-1 PVL at enrolment were more likely to have persistent gen-
ital HPV infection (aOR, 1.60; 95%CI, 1.01–2.56; P = 0.05). Fur-
thermore, persistence of genital HPV infection was more likely
among MLHIV with higher HPV 16 VL at enrolment (aOR,
3.67 per log10 copies/10
6 cells increase, 95% CI, 1.77–7.61).
The ART status or duration on ARTat enrolment was not indepen-
dently associated with persistent anal HPV infection.
Incidence and Clearance of AGW
Of the 304 enrolled MLHIV, 250 (82%) had follow-up
AGWdata available for incidence analysis. A total of 54men were
excluded from incident analysis (36 had prevalent AGW and 18TABLE 2. Associations Between HIV-related Factors and Enrolment HPV
Measure*
N = 8
n (%) or medi
ART status at enrolment
No ART 24 (10.1)
ART 65 (13.6)









Enrolment CD4+ count, cells/μL
≤350 48 (19.1)
>350 38 (8.9)
High stable CD4+ count‡ 12 (13.5)
Detectable HIV-1 PVL at enrolment (>40 copies/mL) 62 (15.0)
Sustained HIV virological control§ 6 (6.7)
Disease control status at enrolment¶
Poorly controlled 52 (16.5)
ART naive 24 (10.1)
Well controlled 11 (7.5)
HPV VL at enrolment||
Log10 HPV 16 copies/10
6 cells 6.32 (5.81–
Log10 HPV 18 copies/10
6 cells 6.01 (5.11–
*N = 89, the total number of infections (68 men had ≥ 1 infection).
†Nine separate GEEmodels for each HIV-related factor were adjusted for ag
presence of AGW.
‡ CD4+ count >500 cells/μL at all follow-up visits.
§ HIV PVL <40 copies/mL at all follow-up visits.
¶ Well-controlled disease defined as on ART for >6 months, CD4+ >350 ce
|| As a continuous variable rounded to the next integer.
350 Sexudid not have at least 1 follow-up visit). These 250 participants
had a total follow-up time of 345.7 person-years, with a median
follow-up time of 1.5 years (range, 0.5–1.9). Only 5 incident cases
of AGW were recorded, translating to an overall AGW incidence
rate of 1.4 per 100 person-years (95% CI, 0.6–3.5).
Of the 36 MLHIV who had AGW at enrolment, 33 (91%)
had data available for analysis of time to AGW clearance. Three
men did not have at least 1 follow-up visit. These 33 men were
followed for a total of 27.2 person-years, with a median duration
of follow-up of 0.6 years (range, 0.4–1.5). A total of 29 men (29
events) had cleared AGW by month 18, giving a clearance rate
of 107.0 events per 100 person-years. The median time to AGW
clearancewas 0.7 years and only 20% had cleared AGWbymonth
6 (IQR, 0.5–1.1; Fig. 1A).Factors Associated With Clearance of AGW
There was a notable inverse dose relationship between
clearance of AGW and CD4+ at enrolment. MLHIV with CD4+
count of at least 350 cells/μL at enrolment were almost 3.7 times
more likely (95% CI, 1.44–9.47, P = 0.007) to clear AGW com-
pared to those with a CD4+ less than 350 cells/μL (Table 3 and
Fig. 1B). Men with well controlled HIV disease at enrolment
were almost 7.5 times more likely to clear AGW compared to
those with poor control (aOR, 7.47; 95% CI, 1.56–35.80,
P = 0.01). No associations were noted between AGW clearance,VL, and Persistent Genital HPV Infection, Using Infections as Unit of
9 Crude Adjusted†
an (IQR) aOR (95% CI) P aOR (95% CI) P
1 1
1.35 (0.92–1.98) 0.13 1.40 (0.84–2.33) 0.20
1 1
1.32 (0.71–2.46) 0.39 1.22 (0.67–2.24) 0.53
2.53 (1.42–4.52) 0.002 1.57 (0.82–3.02) 0.17
1 1
1.59 (0.84–3.00) 0.15 1.45 (0.68–3.09) 0.34
2.41 (1.09–5.29) 0.03 1.97 (0.82–4.74) 0.13
3.65 (2.26–5.90) <0.001 3.54 (2.07–6.05) <0.001
1 1
0.42 (0.28–0.65) <0.001 0.45 (0.28–0.74) <0.001
0.64 (0.36–1.15) 0.14 0.64 (0.35–1.16) 0.14
1.84 (1.19–2.85) 0.01 1.60 (1.01–2.56) 0.05
0.58 (0.26–1.34) 0.20 0.66 (0.29–1.49) 0.32
1
0.60 (0.41–0.87) 0.007 0.65 (0.40–1.07) 0.09
0.41 (0.23–0.75) 0.004 0.50 (0.24–1.05) 0.06
7.62) 1.49 (1.09–2.05) 0.01 3.67 (1.77–7.61) <0.001
6.33) 0.67 (0.44–1.01) 0.06 0.58 (0.43–1.03) 0.07
e, citizenship, employment status, consistent condom use, circumcision and
lls/μL and undetectable PVL.
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Figure 1. Cumulative clearance of AGWs (A) overall and (B) stratified by CD4+ count at enrolment.
Genital HPV Infection and Anogenital Warts in Menand enrolment ART status or duration, or prevalent or persistent
HPV infection (Table 3).
DISCUSSION
In this analysis, we found that 35% of genital HPV infec-
tions persisted for 12 months or more. The incidence rate ofTABLE 3. Factors Associated With Clearance of AGW During Follow-up
No. Events Rate pe
person-years person-y
ART status at enrolment
No ART 8/7.8 101.5
ART 21/19.3 108.8









Enrolment CD4+ count (cells/μL)
≤350 14/15.3 91.4
>350 15/11.4 131.9
High stable CD4+ count† 5/3.6 139.9
Undetectable HIV-1 PVL (<40 copies/mL) 19/17.7 106.8
Sustained HIV virological control‡ 5/4.5 111.9
Disease control status at enrolment§
Poorly controlled 18/17.7 101.4
ART naive 8/7.8 101.4
Well controlled 3/1.5 192.2
Prevalent HPV
Any LR-HPV 26/23.9 108.4
HPV 6 15/14.9 100.6
HPV 11 10/7.8 128.6
Persistent HPV infection
Any LR-HPV 12/11.4 105.0
HPV 6 4/4.5 88.3
HPV 11 2/1.9 106.6
* aHR: associations were adjusted for age, marital status and age at sexual d
† CD4+ count was >500 cells/μL at all follow-up visits.
‡ HIV-1 PVL <40 copies/mL at all follow-up visits.
§ Well-controlled disease defined as on ART for >6 months, CD4+ >350 ce
Sexually Transmitted Diseases • Volume 46, Number 5, May 2019genital infections was 2.9 per 100 person-years. The high propor-
tion of persistent genital HPV infection that we found in our study
is similar to 32% that has been reported among heterosexual
MLHIV in a study in Italy.24 These data show that about a third
of genital HPV infections persist after 12 months and thus could
potentially progress to HPV-related diseases.4 This also suggestsr 100 Crude Adjusted*
ears HR (95% CI) P aHR (95% CI) P
0 1
1 1.16 (0.50–2.76) 0.72 0.97 (0.39–2.39) 0.94
7 1 1
1 1.05 (0.42–2.64) 0.92 0.98 (0.38–2.51) 0.97
0 0.41 (0.09–1.87) 0.25 0.28 (0.05–1.42) 0.12
5 1 1
8 0.47 (0.16–1.33) 0.15 0.51 (0.17–1.52) 0.23
3 0.16 (0.05–0.55) 0.01 0.13 (0.04–0.45) 0.01
5 0.31 (0.09–1.06) 0.06 0.28 (0.08–0.98) 0.05
8 1 1
5 2.89 (1.20–6.96) 0.02 3.69 (1.44–9.46) 0.007
4 2.27 (0.81–6.42) 0.12 2.43 (0.85–6.97) 0.09
3 0.97 (0.445–2.12) 0.94 0.80 (0.34–1.84) 0.59
7 1.05 (0.39–2.82) 0.92 1.01 (0.20–2.16) 0.48
7 1 1
9 0.96 (0.40–2.31) 0.93 1.32 (0.51–3.43) 0.09
3 3.33 (0.91–12.23) 0.07 7.47 (1.56–35.80) 0.01
6 0.75 (0.10–5.71) 0.78 0.63 (0.08–4.93) 0.66
2 0.65 (0.29–1.46) 0.30 0.66 (0.29–1.49) 0.31
5 1.69 (0.75–3.82) 0.21 1.78 (0.77–4.12) 0.18
6 0.82 (0.37–1.79) 0.61 0.97 (0.42–2.27) 0.94
3 0.77 (0.26–2.25) 0.64 0.95 (0.30–3.03) 0.93
4 0.93 (0.22–3.97) 0.92 0.76 (0.17–3.32) 0.71
ebut.
lls/μL and undetectable HIV-1 PVL.
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Chikandiwa et al.that a significant proportion of men infected with HPVwill harbor
the virus and transmit it to their sexual partners.
The incidence rate of AGW, 1.4 per 100 person-years, was
the same as reported from a systematic review of studies from sub-
Saharan Africa.3 The long time to AGW clearance (median,
8.4 months), even when treated with Podophyllin 20% solution, is
concerning. This finding confirms data from a recent systematic re-
view of the current methods for AGW treatment, which highlighted
the need for new and more effective treatment methods, especially
for resource-limited settings.8 It also emphasized that, even though
AGW are benign, they are responsible for considerable morbidity
due psychosocial distress among affected patients and significant
cost implications from several visits to health care facilities for
repeated treatment.25
Similar to previous studies, we found that CD4+ count was
a strong predictor of clearance of genital HPV infection and
AGW.26,27 This relates to the role of cell-mediated immunity in
the clearance of HPV infection.9 However, ART status and duration
on ART at enrolment were not significant predictors, and this is in
keeping with other previous reports.27,28 This suggests that it is
not the ART status per se that is important, but factors, such as
timing of ART initiation, nadir CD4+ count, virological control,
and HIV disease status that influence the natural history of genital
HPV infection. This aligns with our observation in this study that
men with detectable HIV-1 PVL and higher HPV VL were more
likely to have persistent genital HPV infections. Therefore, the cur-
rent initiatives to improve ART coverage by increasing population
HIV testing and immediate treatment initiation may provide benefit
not only for HIV but also for control of HPV infection and AGW.29
The high proportion of persistent genital HPV infections
suggests that HPV vaccination of men could be an effective public
health measure in preventing HPV infection in men as a reservoir
of infection.24 In our cohort, there was only 20% clearance of
AGW at 6-month follow-up. This is less than 44% clearance at
3 month follow-up among women (not living with HIV) reported
in a study in Cape Town.30 The long time to AGW clearance
among MLHIV supports the idea of introducing quadrivalent
HPV vaccines which also prevent AGW. Cost implications of ex-
tending the vaccine to boys might generate reluctance by national
Ministries of Health.31 Evidence from observational studies sug-
gests that single-dose HPV vaccination generates sufficient immune
responses for protection against HPV.32 Randomized control trials
to assess one-dose efficacy are currently underway.33 If these trials
show that 1 dose has high levels of durable protection, this could
make it more affordable and feasible for the HPV vaccine program
to reach more people, including boys and men.
The study had some limitations. Persistence of genital HPV
infections may have been overestimated by assessment of infec-
tion at only 2 timepoints as we cannot rule out clearance of an
HPV type and the reinfection with that same type between the
visits. Likewise, the assessment interval might have been too long
to determine incidence rates because some incident infections
could have already been cleared by the time of the next assess-
ment, leading to underestimation of true incidence rates. Visual in-
spection for AGW detection was done without histological
confirmation, making it possible that other conditions (eg, condylo-
mata lata, pearly penile papules, and penile intraepithelial neoplasia)
could have been misclassified as warts.34 The sample size for HPV
VL was small; therefore, the results on the predictive value of HPV
VL on persistent HPV infection should be interpreted with caution.
In addition, the high proportion of paucicellular specimens suggests
that the method of HPV VL testing might present operational feasi-
bility challenges if it were to be scaled up in the future. It is also im-
portant to note that these data were collected about 4 years ago, and
it is possible that situation might have changed with the maturing of352 Sexuthe HIV program in South Africa. More cohort studies are
required to continue monitoring if some of the findings would
change as the HIV program evolves. However, the guidelines
have changed to immediate ART initiation which will provide
some benefit as men on ART are less likely to shed virus. This
implies that transmission maybe reduced but not eliminated, and
thus, the HPV vaccines might still be required for primary
prevention. Despite these limitations, our study provides a
significant contribution to the scarce data on genital HPV
infection and AGWepidemiology among MLHIV in Africa.
Men living with HIV face a considerable burden of genital
HPV infection and AGWs. The long time to AGW clearance high-
lights the need for more effective treatment for AGW. Effective,
and possibly early, use of ARTwith immunological reconstitution
and HIV virological control may contribute to the control of the
HPV-associated burden. Human papillomavirus vaccination, if ex-
tended to boys, could also reduce this burden amongmen and their
partners in the future.REFERENCES
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